|
2011 Journal Article Palliative care in end-stage kidney diseaseFassett, Robert, Robertson, Ian K., Mace, Rose, Youl, Loren, Challenor, Sarah and Bull, Rosalind (2011). Palliative care in end-stage kidney disease. Nephrology, 16 (1), 4-12. doi: 10.1111/j.1440-1797.2010.01409.x |
|
2011 Conference Publication Ckd.Qld phase 2 survey: Risk factor modification for prevention of progression of chronic kidney diseaseVenuthurupalli, S. K., Salisbury, A., Hoy, W. E., Healy, H. and Fassett, R. G. (2011). Ckd.Qld phase 2 survey: Risk factor modification for prevention of progression of chronic kidney disease. 47th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology, Adelaide, Australia, 19-21 September 2011. Richmond, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/j.1440-1797.2011.01490.x |
|
2011 Journal Article Glutathione peroxidase, superoxide dismutase and catalase genotypes and activities and the progression of chronic kidney diseaseCrawford, Amanda, Fassett, Robert G., Coombes, Jeff S., Kunde, Dale A., Ahuja, Kiran D.K., Robertson, Iain K., Ball, Madeleine J. and Geraghty, Dominic P. (2011). Glutathione peroxidase, superoxide dismutase and catalase genotypes and activities and the progression of chronic kidney disease. Nephrology, Dialysis, Transplantation, 26 (9), 2806-2813. doi: 10.1093/ndt/gfq828 |
|
2011 Conference Publication Atorvastatin Improves Kidney Function in Chronic Kidney Disease Patients Undertaking High Intensity ExerciseFassett, RG, Robertson, IK, Ball, MJ, Geraghty, DP and Coombes, JS (2011). Atorvastatin Improves Kidney Function in Chronic Kidney Disease Patients Undertaking High Intensity Exercise. ANZSN 2011: 47th Annual Scientific Meeting Australian and New Zealand Society of Nephrology, Adelaide, SA, Australia, 19-21 September 2011. MALDEN: WILEY-BLACKWELL. doi: 10.1111/j.1440-1797.2011.01490.x |
|
2011 Conference Publication Views of health professionals about palliative care pathways in patients with chronic kidney disease (ckd)Fassett, R. G., Robertson, I. K., Mace, R., Youl, L., Challenor, S. and Bull, R. (2011). Views of health professionals about palliative care pathways in patients with chronic kidney disease (ckd). 47th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology, Adelaide, Australia, 19-21 September 2011. Richmond, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/j.1440-1797.2011.01490.x |
|
2011 Conference Publication Risk Factor Analysis for Renal Function Outcome in Maintenance Renal Transplant Recipients from the ASCERTAIN Study.Rostaing, L, Fassett, R, Dantal, J, Binet, I, O'Connell, P, Machein, U, Karpov, A, Ulbricht, B and Holdaas, H (2011). Risk Factor Analysis for Renal Function Outcome in Maintenance Renal Transplant Recipients from the ASCERTAIN Study.. American Transplant Congress, Philadelphia Pa, 2011. BLACKWELL MUNKSGAARD. |
|
2011 Conference Publication Factors associated with the progression of chronic kidney disease in nephrology practices in Australia: A retrospective analysis using management software (audit4)Boudville, N., Nelson, C., Fassett, R. G., Pedagogos, E., Healy, H., Mangos, G., Moody, H., Kirkland, G., Kay, T., De Crespigny, P. C., Hoffman, D., Kemp, A. and Waugh, D. (2011). Factors associated with the progression of chronic kidney disease in nephrology practices in Australia: A retrospective analysis using management software (audit4). 47th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology, Adelaide, Australia, 19-21 September 2011. Richmond, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/j.1440-1797.2011.01490.x |
|
2011 Book Chapter Bioactive nutritional supplements for chronic kidney disease: potential cost benefitsGobe, Glenda C., Fassett, Robert G. and Coombes, Jeff S. (2011). Bioactive nutritional supplements for chronic kidney disease: potential cost benefits. Nutrients, dietary supplements, and nutriceuticals: Cost analysis versus clinical benefits. (pp. 301-314) edited by Ronald Ross Watson, Joe K. Gerald and Victor R. Preedy. New York, United States: Springer. doi: 10.1007/978-1-60761-308-4 |
|
2011 Journal Article Biomarkers in chronic kidney disease: A reviewFassett, Robert G., Venuthurupalli, Sree K., Gobe, Glenda C., Coombes, Jeff S., Cooper, Matthew A. and Hoy, Wendy E. (2011). Biomarkers in chronic kidney disease: A review. Kidney International, 80 (8), 806-821. doi: 10.1038/ki.2011.198 |
|
2011 Conference Publication Patterns of progression in chronic kidney disease (pope) study: Baseline dataNelson, C., Fassett, R. G., Boudville, N., Pedagogos, E., Healy, H., Mangos, G., Moody, H., Kirkland, G., Kay, T., De Crespigny, P. C., Hoffman, D. and Waugh, D. (2011). Patterns of progression in chronic kidney disease (pope) study: Baseline data. 47th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology, Adelaide, Australia, 19-21 September 2011. Richmond, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/j.1440-1797.2011.01491.x |
|
2011 Conference Publication Profile of chronic kidney disease practice in Queensland (ckd.Qld phase 2 survey)Venuthurupalli, S. K., Salisbury, A., Hoy, W. E., Healy, H. and Fassett, R. G. (2011). Profile of chronic kidney disease practice in Queensland (ckd.Qld phase 2 survey). 47th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology, Adelaide, Australia, 19-21 September 2011. Richmond, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/j.1440-1797.2011.01490.x |
|
2011 Conference Publication Atorvastatin Slows the Progression of Ckd in Patients with InflammationFassett, RG, Robertson, IK, Ball, MJ, Geraghty, DP and Coombes, JS (2011). Atorvastatin Slows the Progression of Ckd in Patients with Inflammation. ANZSN 2011: 47th Annual Scientific Meeting Australian and New Zealand Society of Nephrology, Adelaide, SA, Australia, 19-21 September 2011. MALDEN: WILEY-BLACKWELL. doi: 10.1111/j.1440-1797.2011.01490.x |
|
2010 Journal Article Effect of atorvastatin on kidney function in chronic kidney disease: a randomised double-blind placebo-controlled trialFassett, Robert G., Robertson, Iain K., Ball, Madeleine J., Geraghty, Dominic P. and Coombes, Jeff S. (2010). Effect of atorvastatin on kidney function in chronic kidney disease: a randomised double-blind placebo-controlled trial. Atherosclerosis, 213 (1), 218-224. doi: 10.1016/j.atherosclerosis.2010.07.053 |
|
2010 Journal Article Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney diseaseBaigent, C., Landray, M., Reith, C., Dasgupta, T., Emberson, J., Herrington, W., Lewis, D., Mafham, M., Collins, R., Bray, C., Chen, Y., Baxter, A., Young, A., Hill, M., Knott, C., Cass, A., Feldt-Rasmussen, B., Fellström, B., Grobbee, R., Grönhagen-Riska, C., Haas, M., Holdaas, H., Hooi, L. S., Jiang, L., Kasiske, B., Krairittichai, U., Levin, A., Massy, Z., Tesar, V. ... Schenck, J. (2010). Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal, 160 (5), 785-794.e10. doi: 10.1016/j.ahj.2010.08.012 |
|
2010 Journal Article Effect of atorvastatin on kidney function in chronic kidney disease: A randomised double-blind placebo-controlled trialFassett, Robert G., Robertson, Iain K., Ball, Madeleine J., Geraghty, Dominic P. and Coombes, Jeff S. (2010). Effect of atorvastatin on kidney function in chronic kidney disease: A randomised double-blind placebo-controlled trial. Atherosclerosis, 213 (1), 218-224. doi: 10.1016/j.atherosclerosis.2010.07.053 |
|
2010 Journal Article Omega-3 polyunsaturated fatty acids in the treatment of kidney diseaseFassett, Robert G., Gobe, Glenda C., Peake, Jonathan M. and Coombes, Jeff S. (2010). Omega-3 polyunsaturated fatty acids in the treatment of kidney disease. American Journal of Kidney Diseases, 56 (4), 728-742. doi: 10.1053/j.ajkd.2010.03.009 |
|
2010 Journal Article A randomized, controlled trial of early versus late initiation of dialysisCooper, Bruce A., Branley, Pauline, Bulfone, Liliana, Collins, John F., Craig, Jonathan C., Fraenkel, Margaret B., Harris, Anthony, Johnson, David W., Kesselhut, Joan, Li, Jing Jing, Luxton, Grant, Pilmore, Andrew, Tiller, David J., Harris, David C., Pollock, Carol A., IDEAL Study Group, Fassett, R. and Healy, H. (2010). A randomized, controlled trial of early versus late initiation of dialysis. New England Journal of Medicine, 363 (7), 609-619. doi: 10.1056/NEJMoa1000552 |
|
2010 Journal Article Randomised controlled trial to determine the appropriate time to initiate peritoneal dialysis after insertion of catheter to minimize complications (Timely PD Study)Ranganathan, Dwarakanathan, Baer, Richard, Fassett, Robert G., Williams, Nicola, Han, Thin, Watson, Melanie and Healy, Helen (2010). Randomised controlled trial to determine the appropriate time to initiate peritoneal dialysis after insertion of catheter to minimize complications (Timely PD Study). BMC Nephrology, 11 (1 Article number 11) 11, 1-5. doi: 10.1186/1471-2369-11-11 |
|
2010 Journal Article Intravenous versus oral rehydration in athletesvan Rosendal, Simon Piet, Osborne, Mark Andrew, Fassett, Robert Gordon, Lancashire, Bill and Coombes, Jeff Scott (2010). Intravenous versus oral rehydration in athletes. Sports Medicine, 40 (4), 327-346. doi: 10.2165/11319810-000000000-00000 |
|
2010 Journal Article Retinal basement membrane abnormalities and the retinopathy of Alport syndromeSavige, Judy, Liu, John, Cabrera DeBuc, Delia, Handa, James T., Hageman, Gregory S., Wang, Yan Yan, Parkin, John D., Vote, Brendan, Fassett, Rob, Sarks, Shirley and Colville, Deb (2010). Retinal basement membrane abnormalities and the retinopathy of Alport syndrome. Investigative Ophthalmology & Visual Science, 51 (3), 1621-1627. doi: 10.1167/iovs.08-3323 |
